{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:49:06Z","timestamp":1787338146560,"version":"build-2736575974"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10674-1","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:34:53Z","timestamp":1749875693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"52","author":[{"given":"Tushara","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Prasad","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanu","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithul","family":"Rajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasmita","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupriya","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajit","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"10674_CR1","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577\u2013e577","journal-title":"Blood Cancer J"},{"key":"10674_CR2","doi-asserted-by":"crossref","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","volume":"19","author":"R Awasthi","year":"2023","unstructured":"Awasthi R, Maier HJ, Zhang J, Lim S (2023) Kymriah\u00ae (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. Hum Vaccin Immunother 19:2210046","journal-title":"Hum Vaccin Immunother"},{"key":"10674_CR3","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","volume":"25","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Farooq U, Ghobadi A (2020) Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist 25:e138\u2013e146","journal-title":"Oncologist"},{"key":"10674_CR4","doi-asserted-by":"crossref","unstructured":"Frey NV (2022) Approval of Brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood 140(1):11\u201315","DOI":"10.1182\/blood.2021014892"},{"key":"10674_CR5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V et al (2023) Lisocabtagene Maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141:1675\u20131684","journal-title":"Blood"},{"key":"10674_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"10674_CR7","doi-asserted-by":"crossref","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T (2022) Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol 13:991092","journal-title":"Front Immunol"},{"key":"10674_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40273-024-01385-9","volume":"42","author":"WL Herring","year":"2024","unstructured":"Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM et al (2024) Cost-effectiveness of lovotibeglogene autotemcel (lovo-Cel) gene therapy for patients with sickle cell disease and recurrent Vaso-occlusive events in the united States. PharmacoEconomics 42:693\u2013714","journal-title":"PharmacoEconomics"},{"key":"10674_CR9","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","volume":"24","author":"RC Marco","year":"2023","unstructured":"Marco RC, Monzo HJ, Ojala PM (2023) CAR T cell therapy: a versatile living drug. Int J Mol Sci 24:6300","journal-title":"Int J Mol Sci"},{"key":"10674_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19:5\u201318","journal-title":"Curr Pharm Biotechnol"},{"key":"10674_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"I Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf I, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139\u2013149","journal-title":"J Exp Med"},{"key":"10674_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X (2017) Engineering car-t cells. Biomark Res 5:1\u20136","journal-title":"Biomark Res"},{"key":"10674_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","volume":"10","author":"S Yu","year":"2017","unstructured":"Yu S, Li A, Liu Q, Li T, Yuan X, Han X et al (2017) Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol OncolJ Hematol Oncol 10:1\u201313","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10674_CR14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D et al (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol 12:813\u2013820","journal-title":"Nat Nanotechnol"},{"key":"10674_CR15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2018.12.013","volume":"39","author":"C-H Jin","year":"2019","unstructured":"Jin C-H, Xia J, Rafiq S, Huang X, Hu Z, Zhou X et al (2019) Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine 39:173\u2013181","journal-title":"EBioMedicine"},{"key":"10674_CR16","doi-asserted-by":"crossref","first-page":"1063454","DOI":"10.3389\/fimmu.2023.1063454","volume":"14","author":"Y Kong","year":"2023","unstructured":"Kong Y, Tang L, You Y, Li Q, Zhu X (2023) Analysis of causes for poor persistence of CAR-T cell therapy in vivo. Front Immunol 14:1063454","journal-title":"Front Immunol"},{"key":"10674_CR17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17:147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"key":"10674_CR18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","volume":"5","author":"M Abou-El-Enein","year":"2024","unstructured":"Abou-El-Enein M (2024) The fate(s) of CAR T-cell therapy: navigating the risks of CAR\u2009+\u2009T-cell malignancy. Blood Cancer Discov 5:249\u2013257","journal-title":"Blood Cancer Discov"},{"key":"10674_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS (2022) CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics 25:69\u201377","journal-title":"Mol Ther Oncolytics"},{"key":"10674_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49\u201362","journal-title":"Nat Rev Clin Oncol"},{"key":"10674_CR21","doi-asserted-by":"crossref","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A (2023) CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern? Front Neurol 14:1144414","journal-title":"Front Neurol"},{"key":"10674_CR22","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl 25:e123\u2013e127","journal-title":"Biol Blood Marrow Transpl"},{"key":"10674_CR23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s43018-021-00277-7","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, Xu J, Chen S-J, Collins MA, Zhou J, Powell DJ Jr et al (2021) Author correction: Engineering-enhanced CAR T cells for improved cancer therapy. Nat Cancer 2:1113","journal-title":"Nat Cancer"},{"key":"10674_CR24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8:1219\u20131226","journal-title":"Cancer Discov"},{"key":"10674_CR25","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N et al (2018) T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 36:2267\u20132280","journal-title":"J Clin Oncol"},{"key":"10674_CR26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","volume":"132","author":"N Hossain","year":"2018","unstructured":"Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S et al (2018) Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies. Blood 132:490","journal-title":"Blood"},{"key":"10674_CR27","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.3390\/ijms21218305","volume":"21","author":"N Hosseinkhani","year":"2020","unstructured":"Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A et al (2020) Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? Int J Mol Sci 21:8305","journal-title":"Int J Mol Sci"},{"key":"10674_CR28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell 36:471\u2013482","journal-title":"Cancer Cell"},{"key":"10674_CR29","doi-asserted-by":"crossref","first-page":"005","DOI":"10.1093\/immadv\/ltac005","volume":"2","author":"R Rossetti","year":"2022","unstructured":"Rossetti R, Brand H, Lima SCG, Furtado IP, Silveira RM, Fantacini DMC et al (2022) Combination of genetically engineered T cells and immune checkpoint Blockade for the treatment of cancer. Immunother Adv 2:005","journal-title":"Immunother Adv"},{"key":"10674_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","volume":"25","author":"X Han","year":"2017","unstructured":"Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y et al (2017) Masked chimeric antigen receptor for tumor-specific activation. Mol Ther 25:274\u2013284","journal-title":"Mol Ther"},{"key":"10674_CR31","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","volume":"12","author":"MA Savanur","year":"2021","unstructured":"Savanur MA, Weinstein-Marom H, Gross G (2021) Implementing logic gates for safer immunotherapy of cancer. Front Immunol 12:780399","journal-title":"Front Immunol"},{"key":"10674_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W (2018) Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res 6:1\u201310","journal-title":"Biomark Res"},{"key":"10674_CR33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971","journal-title":"Cancer Discov"},{"key":"10674_CR34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11:544","journal-title":"Sci Signal"},{"key":"10674_CR35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di, Stasi A (2014) Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 5:254","journal-title":"Front Pharmacol"},{"key":"10674_CR36","doi-asserted-by":"crossref","unstructured":"Gaj T, Gersbach CA, Barbas CF 3 (2013) rd. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 31:397\u2013405","DOI":"10.1016\/j.tibtech.2013.04.004"},{"key":"10674_CR37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","volume":"20","author":"E Noaks","year":"2021","unstructured":"Noaks E, Peticone C, Kotsopoulou E, Bracewell DG (2021) Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Mol Ther Methods Clin Dev 20:675\u2013687","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10674_CR38","doi-asserted-by":"crossref","unstructured":"Short L, Holt RA, Cullis PR, Evgin L (2024) Direct in vivo CAR T cell engineering. Trends Pharmacol Sci 2024;45(5):406\u2013418","DOI":"10.1016\/j.tips.2024.03.004"},{"key":"10674_CR39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"CAR-T cells","year":"2020","unstructured":"CAR-T cells (2020) Hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol 11:1109","journal-title":"Front Immunol"},{"key":"10674_CR40","doi-asserted-by":"crossref","unstructured":"Gumber D, Wang LD (2022) Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine.;77","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"10674_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J (2023) Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol 12:14","journal-title":"Exp Hematol Oncol"},{"key":"10674_CR42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","volume":"144","author":"S Patel","year":"2019","unstructured":"Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G (2019) Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev 144:90\u2013111","journal-title":"Adv Drug Deliv Rev"},{"key":"10674_CR43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","volume":"16","author":"JJ Rennick","year":"2021","unstructured":"Rennick JJ, Johnston AP, Parton RG (2021) Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol 16:266\u2013276","journal-title":"Nat Nanotechnol"},{"key":"10674_CR44","doi-asserted-by":"crossref","first-page":"e2302992","DOI":"10.1002\/advs.202302992","volume":"10","author":"FT Charitidis","year":"2023","unstructured":"Charitidis FT, Adabi E, Ho N, Braun AH, Tierney C, Strasser L et al (2023) CAR gene delivery by T-cell targeted lentiviral vectors is enhanced by Rapamycin induced reduction of antiviral mechanisms. Adv Sci Weinh 10:e2302992","journal-title":"Adv Sci Weinh"},{"key":"10674_CR45","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS et al (2022) Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol 40:1250\u20131258","journal-title":"Nat Biotechnol"},{"key":"10674_CR46","doi-asserted-by":"crossref","unstructured":"Givens BE, Naguib YW, Geary SM, Devor EJ, Salem AK (2018) Nanoparticle-based delivery of CRISPR\/Cas9 genome-editing therapeutics. AAPS J.;20","DOI":"10.1208\/s12248-018-0267-9"},{"key":"10674_CR47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ et al (2024) In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144:977\u2013987","journal-title":"Blood"},{"key":"10674_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L (2024) Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Controlled Release 372:113\u2013140","journal-title":"J Controlled Release"},{"key":"10674_CR49","doi-asserted-by":"crossref","unstructured":"Kim S, Ganesh M, Mugundu AP (2024) Translational PK-PD model for in vivo CAR-T-cell therapy delivered using CAR mRNA-loaded polymeric nanoparticle vector. Clin Transl Sci.;17","DOI":"10.1111\/cts.70101"},{"key":"10674_CR50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H et al (2021) AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J 11:119","journal-title":"Blood Cancer J"},{"key":"10674_CR51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M et al (2024) CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther 15:174","journal-title":"Stem Cell Res Ther"},{"key":"10674_CR52","doi-asserted-by":"crossref","unstructured":"Lonez C, Breman E (2024) Allogeneic CAR-T therapy technologies: has the promise been met? Cells.;13","DOI":"10.3390\/cells13020146"},{"key":"10674_CR53","first-page":"5332","volume":"117","author":"A Biffi","year":"2011","unstructured":"Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M et al (2011) Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood J Am Soc Hematol 117:5332\u20135339","journal-title":"Blood J Am Soc Hematol"},{"key":"10674_CR54","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM et al (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4:13253\u201313253","journal-title":"Sci Transl Med"},{"key":"10674_CR55","doi-asserted-by":"crossref","first-page":"865424","DOI":"10.3389\/fimmu.2022.865424","volume":"13","author":"DL Wagner","year":"2022","unstructured":"Wagner DL, Koehl U, Chmielewski M, Scheid C, Stripecke R (2022) Sustainable clinical development of CAR-T cells\u2013switching from viral transduction towards CRISPR-Cas gene editing. Front Immunol 13:865424","journal-title":"Front Immunol"},{"key":"10674_CR56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/pr10010016","volume":"10","author":"M Al Saber","year":"2021","unstructured":"Al Saber M, Biswas P, Dey D, Kaium MA, Islam MA, Tripty MIA et al (2021) A comprehensive review of recent advancements in cancer immunotherapy and generation of CAR T cell by CRISPR-Cas9. Processes 10:16","journal-title":"Processes"},{"key":"10674_CR57","doi-asserted-by":"crossref","first-page":"360","DOI":"10.14694\/EdBook_AM.2015.35.e360","volume":"35","author":"M Sadelain","year":"2015","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I, Park J (2015) CD19 CAR therapy for acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book 35:360\u2013363","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10674_CR58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/15476286.2019.1582974","volume":"16","author":"A Le Rhun","year":"2019","unstructured":"Le Rhun A, Escalera-Maurer A, Bratovi\u010d M, Charpentier E (2019) CRISPR-Cas in Streptococcus pyogenes. RNA Biol 16:380\u2013389","journal-title":"RNA Biol"},{"key":"10674_CR59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang F, Doudna JA (2017) CRISPR\u2013Cas9 structures and mechanisms. Annu Rev Biophys 46:505\u2013529","journal-title":"Annu Rev Biophys"},{"key":"10674_CR60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg1746","volume":"7","author":"M O\u2019Driscoll","year":"2006","unstructured":"O\u2019Driscoll M, Jeggo PA (2006) The role of double-strand break repair\u2014insights from human genetics. Nat Rev Genet 7:45\u201354","journal-title":"Nat Rev Genet"},{"key":"10674_CR61","doi-asserted-by":"crossref","first-page":"1462697","DOI":"10.3389\/fimmu.2024.1462697","volume":"15","author":"M Amiri","year":"2024","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A (2024) Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front Immunol 15:1462697","journal-title":"Front Immunol"},{"key":"10674_CR62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","volume":"1","author":"K Lee","year":"2017","unstructured":"Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA et al (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 1:889\u2013901","journal-title":"Nat Biomed Eng"},{"key":"10674_CR63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G Oliveira Canedo","year":"2025","unstructured":"Oliveira Canedo G, Roddie C, Amrolia PJ (2025) Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv 9:704\u2013721","journal-title":"Blood Adv"},{"key":"10674_CR64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, Stegen SJ, Hamieh M, Cunanan KM et al (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543:113\u2013117","journal-title":"Nature"},{"key":"10674_CR65","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1002\/cti2.1372","volume":"11","author":"T Kaeuferle","year":"2022","unstructured":"Kaeuferle T, Stief TA, Canzar S, Kutlu NN, Willier S, Stenger D et al (2022) Genome-wide off-target analyses of CRISPR\/Cas9-mediated T-cell receptor engineering in primary human T cells. Clin Transl Immunol 11:e1372","journal-title":"Clin Transl Immunol"},{"key":"10674_CR66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","volume":"28","author":"LT Morton","year":"2020","unstructured":"Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR et al (2020) Simultaneous deletion of endogenous TCR\u03b1\u03b2 for TCR gene therapy creates an improved and safe cellular therapeutic. Mol Ther 28:64\u201374","journal-title":"Mol Ther"},{"key":"10674_CR67","doi-asserted-by":"crossref","unstructured":"Wang Y, Jiang J, Shang K, Xu X, Sun J (2025) Turning trashed genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells. Molecular Therapy","DOI":"10.1016\/j.ymthe.2025.02.028"},{"key":"10674_CR68","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Z\u00fa\u00f1iga CD, Garza-Veloz I, Mart\u00ednez-Rend\u00f3n J, Ure\u00f1o-Segura M, Delgado-Enciso I, Martinez-Fierro ML (2023) Circulating biomarkers associated with the diagnosis and prognosis of B-cell progenitor acute lymphoblastic leukemia. Cancers Basel.;15","DOI":"10.3390\/cancers15164186"},{"key":"10674_CR69","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.3390\/ijms23052755","volume":"23","author":"M Lejman","year":"2022","unstructured":"Lejman M, Cha\u0142upnik A, Chilimoniuk Z, Dobosz M (2022) Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in children. Int J Mol Sci 23:2755","journal-title":"Int J Mol Sci"},{"key":"10674_CR70","doi-asserted-by":"crossref","unstructured":"Moorman AV (2016) New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 2016;101(4):407\u2013416","DOI":"10.3324\/haematol.2015.141101"},{"key":"10674_CR71","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood.V77.9.2016.2016","volume":"77","author":"SC Raimondi","year":"1991","unstructured":"Raimondi SC, Privitera E, Williams DL, Look AT, Behm F, Rivera GK et al (1991) New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood 77:2016\u20132022","journal-title":"Blood"},{"key":"10674_CR72","doi-asserted-by":"crossref","unstructured":"Mullighan C, Wangondu R, Ashcraft E, Chang T-C, Roberts K, Brady S et al (2024) Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Res Sq [Preprint] 2024","DOI":"10.21203\/rs.3.rs-5292018\/v1"},{"key":"10674_CR73","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000075685","volume":"7","author":"RH Carter","year":"2004","unstructured":"Carter RH, Barrington RA (2004) Signaling by the CD19\/CD21 complex on B cells. Curr Dir Autoimmun 7:4\u201332","journal-title":"Curr Dir Autoimmun"},{"key":"10674_CR74","doi-asserted-by":"crossref","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1:36","DOI":"10.1186\/2162-3619-1-36"},{"issue":"Suppl 1","key":"10674_CR75","first-page":"S121","volume":"7","author":"D Thierry-Mieg","year":"2006","unstructured":"Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 7(Suppl 1):S121\u2013S114","journal-title":"Genome Biol"},{"key":"10674_CR76","first-page":"102","volume":"35","author":"LJ Zhou","year":"1992","unstructured":"Zhou LJ, Ord DC, Omori SA, Tedder TF (1992) Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes. Immunogenetics 35:102\u2013111","journal-title":"Immunogenetics"},{"key":"10674_CR77","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0167-5699(94)90273-9","volume":"15","author":"JH Kehrl","year":"1994","unstructured":"Kehrl JH, Riva A, Wilson GL, Th\u00e9venin C (1994) Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 15:432\u2013436","journal-title":"Immunol Today"},{"key":"10674_CR78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/IR:26:1-3:045","volume":"26","author":"RH Carter","year":"2002","unstructured":"Carter RH, Wang Y, Brooks S (2002) Role of CD19 signal transduction in B cell biology. Immunol Res 26:45\u201354","journal-title":"Immunol Res"},{"key":"10674_CR79","doi-asserted-by":"crossref","unstructured":"Qin H, Haso W, Nguyen SM, Fry TJ (2015) Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22","DOI":"10.1182\/blood.V126.23.4427.4427"},{"key":"10674_CR80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/smim.1998.9999","volume":"10","author":"M Fujimoto","year":"1998","unstructured":"Fujimoto M, Poe JC, Inaoki M, Tedder TF (1998) CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 10:267\u2013277","journal-title":"Semin Immunol"},{"key":"10674_CR81","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/eji.201242574","volume":"42","author":"A Schweizer","year":"2012","unstructured":"Schweizer A, W\u00f6hner M, Prescher H, Brossmer R, Nitschke L (2012) Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent Sialic acid analogues. Eur J Immunol 42:2792\u20132802","journal-title":"Eur J Immunol"},{"key":"10674_CR82","doi-asserted-by":"crossref","unstructured":"Siglecs (1998) A family of sialic-acid binding lectins. Glycobiology 8:v\u2013v","DOI":"10.1093\/oxfordjournals.glycob.a018832"},{"key":"10674_CR83","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3083.2002.01063.x","volume":"55","author":"JE Moyron-Quiroz","year":"2002","unstructured":"Moyron-Quiroz JE, Partida-S\u00e1nchez S, Don\u00eds-Hern\u00e1ndez R, Sandoval-Montes C, Santos-Argumedo L (2002) Expression and function of CD22, a B-cell restricted molecule. Scand J Immunol 55:343\u2013351","journal-title":"Scand J Immunol"},{"key":"10674_CR84","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.150.11.4715","volume":"150","author":"EA Clark","year":"1993","unstructured":"Clark EA (1993) CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 150:4715\u20134718","journal-title":"J Immunol"},{"key":"10674_CR85","doi-asserted-by":"crossref","first-page":"673286","DOI":"10.3389\/fgene.2021.673286","volume":"12","author":"L Duan","year":"2021","unstructured":"Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X et al (2021) Nanoparticle delivery of CRISPR\/Cas9 for genome editing. Front Genet 12:673286","journal-title":"Front Genet"},{"key":"10674_CR86","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","volume":"11","author":"N Hoshyar","year":"2016","unstructured":"Hoshyar N, Gray S, Han H, Bao G (2016) The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomed Lond 11:673\u2013692","journal-title":"Nanomed Lond"},{"key":"10674_CR87","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","volume":"22","author":"MB Khawar","year":"2024","unstructured":"Khawar MB, Afzal A, Si Y, Sun H (2024) Steering the course of CAR T cell therapy with lipid nanoparticles. J Nanobiotechnol 22:380","journal-title":"J Nanobiotechnol"},{"key":"10674_CR88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","volume":"159","author":"D Witzigmann","year":"2020","unstructured":"Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R (2020) Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev 159:344\u2013363","journal-title":"Adv Drug Deliv Rev"},{"key":"10674_CR89","doi-asserted-by":"crossref","first-page":"173185","DOI":"10.1016\/j.tibtech.2017.11.006","volume":"36","author":"Z Glass","year":"2018","unstructured":"Glass Z, Lee M, Li YM, Xu QB (2018) Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol 36:173185","journal-title":"Trends Biotechnol"},{"key":"10674_CR90","doi-asserted-by":"crossref","unstructured":"Hughes TS, Langer SJ, Virtanen SI, Chavez RA, Watkins LR, Milligan ED et al (2009) Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression. J Gene","DOI":"10.1002\/jgm.1364"},{"key":"10674_CR91","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"PHDM Prazeres","year":"2023","unstructured":"Prazeres PHDM, Ferreira H, Costa PAC, da Silva W, Alves MT, Padilla M et al (2023) Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int J Nanomed 18:5891\u20135904","journal-title":"Int J Nanomed"},{"key":"10674_CR92","doi-asserted-by":"crossref","unstructured":"Chen F, Alphonse M, Liu Q (2020) Strategies for nonviral nanoparticle-based delivery of CRISPR\/Cas9 therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(3):e1609","DOI":"10.1002\/wnan.1609"},{"key":"10674_CR93","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.addr.2008.03.016","volume":"60","author":"P Ghosh","year":"2008","unstructured":"Ghosh P, Han G, De M, Kim CK, Rotello VM (2008) Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60:1307\u20131315","journal-title":"Adv Drug Deliv Rev"},{"key":"10674_CR94","first-page":"e2586","volume":"7","author":"R Mout","year":"2017","unstructured":"Mout R, Rotello VM (2017) Cytosolic and nuclear delivery of CRISPR\/Cas9- ribonucleoprotein for gene editing using arginine functionalized gold nanoparticles. Bio Protoc 7:e2586","journal-title":"Bio Protoc"},{"key":"10674_CR95","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1002\/anie.201506030","volume":"54","author":"W Sun","year":"2015","unstructured":"Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL et al (2015) Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl 54:12029\u201312033","journal-title":"Angew Chem Int Ed Engl"},{"key":"10674_CR96","first-page":"525","volume-title":"Methods mol biol","author":"I Nakase","year":"2011","unstructured":"Nakase I, Kogure K, Harashima H, Futaki S (2011) Application of a fusiogenic peptide GALA for intracellular delivery. Methods mol biol. Humana, Totowa, NJ, pp 525\u2013533"},{"key":"10674_CR97","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 4:e10143","journal-title":"Bioeng Transl Med"},{"key":"10674_CR98","doi-asserted-by":"crossref","unstructured":"Fam S (2020) Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials.;10","DOI":"10.3390\/nano10040787"},{"key":"10674_CR99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J (2014) Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61:163\u2013173","journal-title":"Mol Immunol"},{"key":"10674_CR100","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9:1410","journal-title":"Nat Commun"},{"key":"10674_CR101","doi-asserted-by":"crossref","first-page":"1903164","DOI":"10.1002\/advs.201903164","volume":"7","author":"AM Abdalla","year":"2020","unstructured":"Abdalla AM, Xiao L, Miao Y, Huang L, Fadlallah GM, Gauthier M et al (2020) Nanotechnology promotes genetic and functional modifications of therapeutic T cells against cancer. Adv Sci 7:1903164","journal-title":"Adv Sci"},{"key":"10674_CR102","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0142-9612(99)00021-6","volume":"20","author":"MT Peracchia","year":"1999","unstructured":"Peracchia MT, Harnisch S, Pinto-Alphandary H (1999) Visualization of in vitro protein- rejecting properties of pegylated stealth polycyanoacrylate nanoparticles. Biomaterials 20:1269\u20131275","journal-title":"Biomaterials"},{"key":"10674_CR103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24:225\u2013232","journal-title":"Curr Opin Immunol"},{"key":"10674_CR104","doi-asserted-by":"crossref","unstructured":"Bisikirska (2005) TCR stimulation with modified anti-CD3 mAb expands CD8\u2009+\u2009T cell population and induces CD8\u2009+\u2009CD25\u2009+\u2009Tregs. J Clin Invest 115:2904\u20132913","DOI":"10.1172\/JCI23961"},{"key":"10674_CR105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M et al (2025) From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med 23:10","journal-title":"J Transl Med"},{"key":"10674_CR106","doi-asserted-by":"crossref","unstructured":"Behr M, Zhou J, Xu B, Zhang H, B APS (2021) In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges. Acta Pharm Sin B 11(8):2150\u20132171","DOI":"10.1016\/j.apsb.2021.05.020"},{"key":"10674_CR107","doi-asserted-by":"crossref","unstructured":"Zhang X (2023) GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Front Immunol.;14","DOI":"10.3389\/fimmu.2023.1103695"},{"key":"10674_CR108","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","volume":"14","author":"T Wei","year":"2020","unstructured":"Wei T, Cheng Q, Farbiak L, Anderson DG, Langer R, Siegwart DJ (2020) Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-based genome editing. ACS Nano 14:9243\u20139262","journal-title":"ACS Nano"},{"key":"10674_CR109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20:101\u2013124","journal-title":"Nat Rev Drug Discov"},{"key":"10674_CR110","doi-asserted-by":"crossref","first-page":"1671761","DOI":"10.1080\/2162402X.2019.1671761","volume":"8","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Weidner T, Thalheimer FB, Buchholz CJ (2019) In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology 8:1671761","journal-title":"Oncoimmunology"},{"key":"10674_CR111","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/bi9602019","volume":"35","author":"Y Xu","year":"1996","unstructured":"Xu Y, Szoka FC Jr. (1996) Mechanism of DNA release from cationic liposome\/dna complexes used in cell transfection. Biochemistry 35:5616\u20135623","journal-title":"Biochemistry"},{"key":"10674_CR112","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z et al (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490\u2013495","journal-title":"Nature"},{"key":"10674_CR113","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","volume":"105","author":"T Ishida","year":"2005","unstructured":"Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H (2005) Accelerated blood clearance of pegylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 105:305\u2013317","journal-title":"J Control Release"},{"key":"10674_CR114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2005.01.008","volume":"104","author":"XY Wang","year":"2005","unstructured":"Wang XY, Ishida T, Ichihara M, Kiwada H (2005) Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release 104:91\u2013102","journal-title":"J Control Release"},{"key":"10674_CR115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14:282\u2013295","journal-title":"AAPS J"},{"key":"10674_CR116","doi-asserted-by":"crossref","unstructured":"Kiru L (2022) In vivo imaging of nanoparticle-labeled CAR T cells. Proc Natl Acad Sci.;119","DOI":"10.1073\/pnas.2102363119"},{"key":"10674_CR117","doi-asserted-by":"crossref","first-page":"111273","DOI":"10.1016\/j.intimp.2023.111273","volume":"126","author":"D Zhang","year":"2024","unstructured":"Zhang D, Lyu L, Han S, Xu J, Hu G, Zhao Q et al (2024) Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials. Int Immunopharmacol 126:111273","journal-title":"Int Immunopharmacol"},{"key":"10674_CR118","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10555-024-10185-8","volume":"43","author":"R Hou","year":"2024","unstructured":"Hou R, Zhang X, Wang X, Zhao X, Li S, Guan Z et al (2024) In vivo manufacture and manipulation of CAR-T cells for better druggability. Cancer Metastasis Rev 43:1075\u20131093","journal-title":"Cancer Metastasis Rev"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10674-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:34:10Z","timestamp":1766853250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10674-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10674"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10674-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"596"}}